Design Therapeutics Inc
NASDAQ:DSGN

Watchlist Manager
Design Therapeutics Inc Logo
Design Therapeutics Inc
NASDAQ:DSGN
Watchlist
Price: 6.25 USD 4.34%
Market Cap: 353.9m USD
Have any thoughts about
Design Therapeutics Inc?
Write Note

Design Therapeutics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Design Therapeutics Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Design Therapeutics Inc
NASDAQ:DSGN
Income from Continuing Operations
-$66.9m
CAGR 3-Years
-101%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Design Therapeutics Inc
Glance View

Market Cap
353.9m USD
Industry
Biotechnology

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.

DSGN Intrinsic Value
4.98 USD
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Design Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-66.9m USD

Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Income from Continuing Operations amounts to -66.9m USD.

What is Design Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-101%

Over the last year, the Income from Continuing Operations growth was -6%. The average annual Income from Continuing Operations growth rates for Design Therapeutics Inc have been -101% over the past three years .

Back to Top